The Best Treatment for Low-Risk Prostate Cancer? Depends on the Patient.
Careful monitoring of low-risk prostate cancer...
Read more
Read more
Archive for November, 2010
New technique to speed up drug development
Scientists working at the European Molecular...
Read more
Read more
Reasons Why mHealth Apps Matters for Pharma
The potential of mHealth solutions has been...
Read more
Read more
Women With Migraine With Aura Have Better Outcomes After Stroke
Study Highlights: – Female stroke survivors...
Read more
Read more
Women With Migraine With Aura Have Better Outcomes After Stroke
Study Highlights: – Female stroke survivors...
Read more
Read more
Life Sciences Industry Survey: FDA Has a Ways to Go
Some 38% of 50 life-sciences companies surveyed...
Read more
Read more
Life Sciences Industry Survey: FDA Has a Ways to Go
Some 38% of 50 life-sciences companies surveyed...
Read more
Read more
CDC: Most Americans Still Haven’t Been Tested for AIDS Virus
The good news: 11.4 million more people have been...
Read more
Read more
Array BioPharma to Present ARRY-520 / KSP Inhibitor Data at 2010 ASH Annual Meeting
BOULDER, Colo.–(BUSINESS WIRE)–Nov...
Read more
Read more
Keryx Biopharmaceuticals to Hold Conference Call Tomorrow at 8:30 AM ET to Discuss Top-Line Results from Zerenex Phase 3 Short-Term Study
NEW YORK, Nov. 29, 2010 /PRNewswire-FirstCall/...
Read more
Read more
New MRI Data Confirm Simponi (Golimumab) Efficacy in Treatment of Rheumatoid Arthritis
MONTREAL, Nov. 30 /CNW/ – Magnetic...
Read more
Read more
Cytheris announces publication of clinical case study combining recombinant human interleukin-7 (CYT107) with antiviral agent CMX001 as potential…
Combination therapy with two investigational...
Read more
Read more
Optimer Pharmaceuticals Completes New Drug Application for Fidaxomicin and Requests Priority Review From FDA
SAN DIEGO, Nov. 30, 2010 /PRNewswire-FirstCall/...
Read more
Read more
Optimer Pharmaceuticals Completes New Drug Application for Fidaxomicin and Requests Priority Review From FDA
SAN DIEGO, Nov. 30, 2010 /PRNewswire-FirstCall/...
Read more
Read more
Can Too Much Vitamin D Be Hazardous to Your Health?
The group set the upper limit of safe consumption...
Read more
Read more
Keryx Biopharmaceuticals Announces Highly Statistically Significant Positive Results From Phase 3 Study of Zerenex (Ferric Citrate) for the Treatment…
Study Meets Primary and Key Secondary Endpoints...
Read more
Read more
10th Colloque Médecine et Recherche of the Fondation Ipsen in the Endocrinology Series: ?Multi-System Endocrine Disruption?
PARIS–(BUSINESS WIRE)–Nov 30, 2010...
Read more
Read more
Lubiprostone Successfully Completes Long-Term Phase 3 Safety Trial in Japanese Patients with Chronic Idiopathic Constipation
BETHESDA, Md. & ABBOTT PARK,...
Read more
Read more
NYT: Psych text ghostwritten by pharma
Two doctors who’ve previously drawn...
Read more
Read more
NYT: Psych text ghostwritten by pharma
Two doctors who’ve previously drawn...
Read more
Read more
New Data on Vimpat (lacosamide) C-V to be Presented at the 64th Annual Meeting of the American Epilepsy Society
Data on Keppra XR (levetiracetam) extended...
Read more
Read more
New Data on Vimpat (lacosamide) C-V to be Presented at the 64th Annual Meeting of the American Epilepsy Society
Data on Keppra XR (levetiracetam) extended...
Read more
Read more
Biosimilars threaten Big Pharma’s older biologics
A lineup of blockbuster monoclonal antibodies...
Read more
Read more
Biosimilars threaten Big Pharma’s older biologics
A lineup of blockbuster monoclonal antibodies...
Read more
Read more
FDA nod raises hopes for Ranbaxy resolution
Does the FDA’s blessing of a new generic...
Read more
Read more